Sarepta’s DMD Gene Therapy: FDA Says Concluding Effectiveness Or Ineffectiveness Is ‘Challenging’

Concerns about the clinical trials, the manufacturing, and the preclusive nature of Sarepta's gene therapy for Duchenne muscular dystrophy raise questions ahead of the upcoming US FDA advisory committee meeting.

Gene therapy
The FDA said that Sarepta's commercial manufacturing process was not comparable to the process used to make SRP-9001 for early clinical studies. • Source: Shutterstock

US Food and Drug Administration reviewers are unsure whether Sarepta Therapeutics, Inc.’s Duchenne muscular dystrophy gene therapy candidate is effective, raising questions about the product’s ability to gain accelerated approval.

And even though the agency has granted accelerated approval to several DMD drugs despite concerns about the validity of their...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers